Daily peanuts for fullness, diet quality, and body composition
Dietary Peanut Intake and Nutrition-Related Outcomes in Individuals Using GLP-1 Receptor Agonists: A Randomized Controlled Trial
This study will test whether eating peanuts every day for 12 weeks helps adults taking GLP‑1 medicines feel fuller, have more energy, and improve weight and body composition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University Hospitals Cleveland Medical Center Academic / other |
| Locations | 1 site (Clevland, Ohio) |
| Trial ID | NCT07244458 on ClinicalTrials.gov |
What this trial studies
This interventional study enrolls adults with obesity or overweight plus a weight-related comorbidity who have been using semaglutide or tirzepatide for at least six months. Participants will add a daily portion of peanuts to their meals for 12 weeks and undergo body composition assessment by DEXA, blood tests, and questionnaires on satiety, energy, and eating enjoyment. Investigators will track changes in weight-related outcomes, dietary quality, and selected health markers. The aim is to see if peanuts can boost fullness and overall nutrition without undermining weight management in people already on GLP‑1 receptor agonists.
Who should consider this trial
Good fit: Adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been taking semaglutide or tirzepatide for at least six months, are not allergic to nuts, and can attend in-person visits in Cleveland, Ohio.
Not a fit: People with a known nut allergy, those not using or with contraindications to GLP‑1 receptor agonists, pregnant or breastfeeding individuals, and incarcerated persons are excluded and would not receive benefit from participation.
Why it matters
Potential benefit: If successful, adding daily peanuts could increase satiety and improve diet quality and body composition for adults taking GLP‑1 medications.
How similar studies have performed: Previous trials of daily nut consumption have often shown improved satiety and diet quality without causing weight gain, but applying this approach specifically to people on GLP‑1 medications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals with a BMI ≥30 kg/m2 or with a BMI ≥27 kg/m2 with at least one weight-related comorbidity who have been using semaglutide or tirzepatide for a clinical indication or at least 6 months Exclusion Criteria: * No use or contraindication to use of a GLP-1 RA * Known allergy to nuts * Pregnant or breastfeeding * Incarcerated
Where this trial is running
Clevland, Ohio
- University Hospitals Cleveland Medical Center — Clevland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Ian Neeland, MD — University Hospitals Cleveland Medical Center
- Study coordinator: Ian Neeland, MD
- Email: Ian.Neeland@UHhospitals.org
- Phone: 216-844-5965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.